前列腺癌
医学
神经内分泌分化
肿瘤科
前列腺
神经内分泌肿瘤
癌症
内科学
肺癌
作者
Busola R. Alabi,Shiqin Liu,Tanya Stoyanova
标识
DOI:10.1016/j.pharmthera.2022.108255
摘要
Neuroendocrine prostate cancer is a histological variant of prostate cancer that is characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine markers. Neuroendocrine prostate cancer usually manifests in late-stage prostate cancer patients who have undergone multiple rounds of anti-androgen therapies but can, although rarely, occur in treatment naïve patients de novo. Current therapies to treat neuroendocrine prostate cancer are largely based on their success in treating patients with small cell lung cancer, a lung cancer that shares the neuroendocrine phenotype with neuroendocrine prostate cancer. However, unfortunately these therapies are not durable. In this review, we discuss therapies currently in use to treat neuroendocrine prostate cancer, including platinum-based therapies, taxanes and etoposide. Additionally, we utilize ongoing clinical trials information to identify potential emerging therapies for neuroendocrine prostate cancer. Lastly, we discuss additional potential future opportunities for targeting neuroendocrine prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI